Vogt-Koyanagi-Harada Syndrome

REFERENCES

• Sheu S J. Update on uveomeningoencephalitides. Curr Opin Neurol. 2005; 18: 323–329
   PubMed Web of Science ®Google Scholar
• Moorthy R S, Inomata H, Rao N A. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 1995; 39: 265–292
   PubMed Web of Science ®Google Scholar
• Mondkar S V, Biswas J, Ganesh S K. Analysis of 87 cases with Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 2000; 44: 296–301
   PubMed Web of Science ®Google Scholar
• Yang P, Ren Y, Li B, et al. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology 2007; 114: 606–614
   PubMed Web of Science ®Google Scholar
• Chee S P, Luu C D, Cheng C L, et al. Visual function in Vogt-Koyanagi-Harada patients. Graefe's Arch Clin Exp Ophthalmol 2005; 243: 785–790
   PubMed Web of Science ®Google Scholar
• Bykhovskaya I, Thorne J E, Kempen J H, et al. Vogt-Koyanagi-Harada disease: Clinical outcomes. Am J Ophthalmol 2005; 140: 674–678
   PubMed Web of Science ®Google Scholar
• Herbort C P, Mochizuki M. Vogt-Koyanagi-Harada disease: Inquiry into the genesis of a disease name in the historical context of Switzerland and Japan. Int Ophthalmol. 2007; 27: 67–79
   PubMedGoogle Scholar
• Wakabayashi T, Morimura Y, Miyamoto Y, et al. Changing patterns of intraocular inflammatory disease in Japan. Ocul Immunol Inflamm 2003; 11: 277–286
   PubMed Web of Science ®Google Scholar
• Murthy S I, Moreker M R, Sangwan V S, et al. The spectrum of Vogt-Koyanagi-Harada disease in South India. Int Ophthalmol 2007; 27: 131–136
   PubMedGoogle Scholar
• Singh R, Gupta V, Gupta A. Pattern of uveitis in a referral eye care clinic in North India. Indian J Ophthalmol. 2004; 52: 121–125
   PubMedGoogle Scholar
• Chee S P, Jap A, Bacsal K. Spectrum of Vogt-Koyanagi-Harada disease in Singapore. Int Ophthalmol 2007; 27: 137–142
   PubMedGoogle Scholar
• Rajendram R, Evans M, Rao N A. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin 2005; 45: 115–134
   PubMedGoogle Scholar
• Sukavatcharin S, Tsai J H, Rao N A. Vogt-Koyanagi-Harada disease in Hispanic patients. Int Ophthalmol. 2007; 27: 143–148
   PubMedGoogle Scholar
• Damico F M, Kiss S, Young L H. Vogt-Koyanagi-Harada disease. Semin Ophthalmol 2005; 20: 183–190
   PubMedGoogle Scholar
• Khairallah M, Zaouali S, Messaoud R, et al. The spectrum of Vogt-Koyanagi-Harada disease in Tunisia, North Africa. Int Ophthalmol. 2007; 27: 125–130
   PubMedGoogle Scholar
• Khairallah M, Yahia S B, Ladjimi A, et al. Pattern of uveitis in a referral center in Tunisia, North Africa. Eye. 2007; 21: 33–39
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Ozyazgan Y, Akova Y A, et al. The spectrum of Vogt-Koyanagi-Harada disease in Turkey: VKH in Turkey. Int Ophthalmol 2007; 27: 117–123
   PubMedGoogle Scholar
• Soheilian M, Aletaha M, Yazdani S, et al. Management of pediatric Vogt-Koyanagi-Harada (VKH)-associated panuveitis. Ocul Immunol Inflamm 2006; 14: 91–98
   PubMed Web of Science ®Google Scholar
• Berker N, Ozdamar Y, Soykan E, et al. Vogt-Koyanagi-Harada syndrome in children: Report of a case and review of the literature. Ocul Immunol Inflamm 2007; 15: 351–357
   PubMed Web of Science ®Google Scholar
• Ikeda N, Hayasaka S, Hayasaka Y. Uveitis and pseudouveitis presenting for the first time in Japanese elderly patients. Ophthalmologica. 2005; 219: 263–266
   PubMed Web of Science ®Google Scholar
• Yang P, Zhang Z, Zhou H, et al. Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China. Curr Eye Res 2005; 30: 943–948
   PubMed Web of Science ®Google Scholar
• Read R W. Vogt-Koyanagi-Harada disease. Ophthalmol Clin North Am. 2002; 15: 333–341
   PubMedGoogle Scholar
• Snyder D A, Tessler H H. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1980; 90: 69–75
   PubMed Web of Science ®Google Scholar
• Yamaki K, Gocho K, Hayakawa K, et al. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol. 2000; 165: 7323–7329
   PubMed Web of Science ®Google Scholar
• Sugita S, Takase H, Taguchi C, et al. Ocular infiltrating CD4+ T cells from patients with Vogt–Koyanagi–Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci. 2006; 47: 2547–2554
   PubMed Web of Science ®Google Scholar
• Chi W, Yang P, Li B, et al. IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol 2007; 119: 1218–1224
   PubMed Web of Science ®Google Scholar
• Horie Y, Takemoto Y, Miyazaki A, et al. Tyrosinase gene family and Vogt-Koyanagi-Harada disease in Japanese patients. Mol Vis 2006; 12: 1601–1605
   PubMed Web of Science ®Google Scholar
• Otani S, Sakurai T, Yamamoto K, et al. Frequent immune response to a melanocyte specific protein KU-MEL-1 in patients with Vogt-Koyanagi-Harada disease. Br J Ophthalmol 2006; 90: 773–777
   PubMed Web of Science ®Google Scholar
• Andreoli C M, Foster C S. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin 2006; 46: 111–122
   PubMedGoogle Scholar
• Shindo Y, Inoko H, Yamamoto T, et al. HLA-DRB1 typing of VKH disease by PCR-RLP and the strong association with DRB1*0405 and DRB1*0410. Br J Ophthalmol 1994; 78: 223–226
   PubMed Web of Science ®Google Scholar
• Damico F M, Cunha-Neto E, Goldberg A C, et al. T-cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA-DRB1*0405-positive and -negative Vogt-Koyanagi-Harada uveitis. Invest Ophthalmol Vis Sci 2005; 46: 2465–2471
   PubMed Web of Science ®Google Scholar
• Kim M H, Seong M C, Kwak N H, et al. Association of HLA with Vogt-Koyanagi-Harada syndrome in Koreans. Am J Ophthalmol 2000; 129: 173–177
   PubMed Web of Science ®Google Scholar
• Gupta A, Kamal S, Gupta V, et al. HLA typing in Vogt-Koyanagi-Harada syndrome in North Indian patients. Ocul Immunol Inflamm 2007; 15: 89–97
   PubMed Web of Science ®Google Scholar
• Itho S, Kurimoto S, Kouno T. Vogt-Koyanagi-Harada disease in monozygotic twins. Int Ophthalmol 1992; 16: 49–54
   PubMed Web of Science ®Google Scholar
• Du L, Yang P, Hou S, et al. Association of the CTLA-4 gene with Vogt-Koyanagi-Harada syndrome. Clin Immunol 2008; 127(1)43–48
   PubMed Web of Science ®Google Scholar
• Bassili S S, Peyman G A, Gebhardt B M, et al. Detection of Epstein-Barr virus DNA by polymerase chain reaction in the vitreous from a patient with Vogt-Koyanagi-Harada syndrome. Retina. 1996; 16: 160–161
   PubMed Web of Science ®Google Scholar
• Sugita S, Takase H, Kawaguchi T, et al. Cross-reaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007; 27: 87–95
   PubMedGoogle Scholar
• Touitou V, Bodaghi B, Cassoux N, et al. Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C. Am J Ophthalmol. 2005; 140: 949–952
   PubMed Web of Science ®Google Scholar
• Sene D, Touitou V, Bodaghi B, et al. Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol 2007; 13: 3137–3140
   PubMed Web of Science ®Google Scholar
• Kasahara A, Hiraide A, Tomita N, et al. Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C. J Gastroenterol 2004; 39: 1106–1109
   PubMed Web of Science ®Google Scholar
• Norose K, Yano A. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. Br J Ophthalmol 1996; 80: 1002–1008
   PubMed Web of Science ®Google Scholar
• Imai Y, Sugita M, Nakamura S, Toriyama S, Ohno S. Cytokine production and helper T cell subsets in Vogt-Koyanagi-Harada's disease. Curr Eye Res. 2001; 22: 312–318
   PubMed Web of Science ®Google Scholar
• Li B, Yang P, Zhou H, et al. Upregulation of T-bet expression in peripheral blood mononuclear cells during Vogt-Koyanagi-Harada disease. Br J Ophthalmol 2005; 89: 1410–1412
   PubMed Web of Science ®Google Scholar
• Langrish C L, Chen Y, Blumenschein W M, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233–240
   PubMed Web of Science ®Google Scholar
• Amadi-Obi A, Yu C R, Liu X, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007; 13: 711–718
   PubMed Web of Science ®Google Scholar
• Luger D, Caspi R R. New perspectives on effector mechanism in uveitis. Semin Immunopathol 2008; 30: 135–143
   PubMed Web of Science ®Google Scholar
• Luger D, Silver P B, Tang J, et al. Either a Th 17 or a Th 1 effector response can drive autoimmunity: Conditions of disease induction affect dominant effector category. J Exp Med. 2008; 205: 799–810
   PubMed Web of Science ®Google Scholar
• Yang P, Chen L, Zhou H, et al. Resistance of lymphocytes to Fas-mediated apoptosis in Behçet's disease and Vogt-Koyangi-Harada syndrome. Ocul Immunol Inflamm 2002; 10: 47–52
   PubMed Web of Science ®Google Scholar
• Kitamura M, Kitaichi N, Takeuchi M, et al. Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2005; 89: 1407–1409
   PubMed Web of Science ®Google Scholar
• Inomata H, Rao N A. Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001; 131: 607–614
   PubMed Web of Science ®Google Scholar
• Read R W, Holland G N, Rao N A, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: Report of an international committee on nomenclature. Am J Ophthalmol. 2001; 131: 647–652
   PubMed Web of Science ®Google Scholar
• Ladas J G, Wheeler N C, Morhun P J, et al. Laser flare-cell photometry: Methodology and clinical applications. Surv Ophthalmol. 2005; 50: 27–47
   PubMed Web of Science ®Google Scholar
• Fang W, Zhou H, Yang P, et al. Longitudinal quantification of aqueous flare and cells in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2008; 92: 182–185
   PubMed Web of Science ®Google Scholar
• Yang P, Fang W, Wang L, et al. Study of macular function by multifocal electroretinography (mfERG) in patients with Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 2008, (in press)
   Web of Science ®Google Scholar
• Yang P, Fang W, Zhou H, et al. Alterations of color vision and central visual field in patients with Vogt-Koyanagi-Harada syndrome, Submitted for publication
   Google Scholar
• Rao N A, Moorthy R S, Inomata H. Vogt-Koyanagi-Harada syndrome. Int Ophthalmol Clin. 1995; 35: 69–86
   PubMedGoogle Scholar
• Yamanaka E, Ohguro N, Yamamoto S, et al. Evaluation of pulse corticosteroid therapy for Vogt-Koyanagi-Harada disease assessed by optical coherence tomography. Am J Ophthalmol. 2002; 134: 454–456
   PubMed Web of Science ®Google Scholar
• Read R W, Yu F, Accorinti M, et al. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2006; 142: 119–124
   PubMed Web of Science ®Google Scholar
• Foster C S, Vitale A T. Immunosuppressive chemotherapy. Diagnosis and Treatment of Uveitis, C Foster, A Vitale. WB Saunders, New York 2002; 177–214
   Google Scholar
• Lustig M J, Cunningham E T, Jr. Use of immunosuppressive agents in uveitis. Curr Opin Ophthalmol. 2003; 14: 399–412
   PubMedGoogle Scholar
• Goldstein D A, Fontanilla F A, Kaul S, et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology. 2002; 109: 370–377
   PubMed Web of Science ®Google Scholar
• Agarwal M, Ganesh S K, Biswas J. Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm 2006; 14: 333–339
   PubMed Web of Science ®Google Scholar
• Paredes I, Ahmed M, Foster C S. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006; 14: 87–90
   PubMed Web of Science ®Google Scholar
• Foster D J, Rao N A, Hill R A, et al. Incidence and management of glaucoma in Vogt-Koyanagi-Harada syndrome. Ophthalmology. 1993; 100: 613–618
   PubMed Web of Science ®Google Scholar
• Ganesh S K, Padmaja B K, et al. Cataract surgery in patients with Vogt-Koyanagi-Harada syndrome. J Cataract Refract Surg 2004; 30: 95–100
   PubMed Web of Science ®Google Scholar
• Farah M E, Costa R A, Muccioli C, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 2002; 134: 137–139
   PubMed Web of Science ®Google Scholar
• Nowilaty S R, Bouhaimed M. Photodynamic therapy study group. Photodynamic therapy for subfoveal choroidal neovascularization in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 2006; 90: 982–986
   PubMed Web of Science ®Google Scholar
• Read R W, Rechodouni A, Butani N, et al. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001; 131: 599–606
   PubMed Web of Science ®Google Scholar
• Al-Kharashi A S, Aldibhi H, Al-Fraykh H, et al. Prognostic factors in Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007; 27: 201–210
   PubMedGoogle Scholar